Revisiting the CATIE schizophrenia study
A long-term trial of schizophrenia drugs has found that newer medications are not any more effective than a first-generation drug, but questions have been raised about the parameters of the study.
A long-term trial of schizophrenia drugs has found that newer medications are not any more effective than a first-generation drug, but questions have been raised about the parameters of the study.
The World Health Organization found that many people worldwide are not receiving needed mental health care and services.
I’m just recovering from the flu and am wondering how quickly I can safely get back to my workouts. I’ve read that doing too much too soon can increase the risk of heart infections. What is “too much, too soon” in this case?
Does high blood sugar cause muscle pain?
I have a problem with hair loss. After I came back from Iraq I started losing hair in small patches, first on my beard and then on my scalp. Could my hair loss be caused by a fungus rather than stress?
In experiments on mice, suppressing a chemical linked to stress and appetite prevented the formation of abdominal fat cells, which could lead to new possibilities for weight loss drugs.
Reports in a medical journal claim that Merck & Co. paid outside scientists to be listed as authors of articles written by ghostwriters. The articles included research on Vioxx. This drug was withdrawn from the market in 2004 because of heart and stroke risks. The new reports also say that Merck tried to minimize the death risk in two studies related to Vioxx and Alzheimer’s disease. But Merck told the Associated Press that the new reports were false and misleading. It said the listed authors were closely involved in the research. Merck said the Alzheimer’s articles were accurate. The company also said the new reports were biased because their authors had consulted for people who sued Merck over Vioxx. The reports were published April 16 in the Journal of the American Medical Association.
Mixed results in tests of medications for the treatment of ADHD have led to interest in neurofeedback as a possible alternative, but research into its effectiveness has not been conclusive so far.
Research into the genetic origins of schizophrenia and bipolar disorder suggests that, while distinct, the two mental illnesses are more alike than different.